Gabapentin for the treatment of alcohol use disorder

References

• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global status report on alcohol and health – p. XIV, 2014 ed. Geneva: World Health Organization. 2014. Last accessed 2017 Dec 6. Available at: http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_1.pdf
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Press. 2013.
   Google Scholar
• Gordis E. Relapse and craving: a commentary. Alcohol Alert. 1989;6:3.
   PubMedGoogle Scholar
• Geller A. Protracted abstinence. In: Miller NS, ed.. Comprehensive handbook of drugs and alcohol addiction. New York, NY: Marcel Dekker; 1991. p. 905–913.
   Google Scholar
• Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11–34.
   PubMed Web of Science ®Google Scholar
• Lowman C, Allen J, Stout RL. Replication and extension of Marlatt’s taxonomy of relapse precipitants: overview of procedures and results. The relapse research group. Addiction. 1996;91(S51):71.
   Google Scholar
• Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcoholism Clin Exp Res. 1998;22(8):1864–1871.
   PubMed Web of Science ®Google Scholar
• Foster JH, Peters TJ. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcoholism Clin Exp Res. 1999;23(6):1044–1051.
   PubMed Web of Science ®Google Scholar
• Clark CP, Gillin JC, Golshan S, et al. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression. Biol Psychiatry. 1998;43:601–607.
   PubMed Web of Science ®Google Scholar
• Gillin JC, Smith TL, Irwin M, et al. Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with primary alcoholism at 3-month follow-up. Arch Gen Psychiatry. 1994;51:189–197.
   PubMed Web of Science ®Google Scholar
• The. ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Heath Organization; 1992.
   Google Scholar
• World Health Organization. ICD-11 Beta Draft. Geneva: World Health Organization. 2016. Last accessed 2017 Dec 6. Available at: https://icd.who.int/dev11/l-m/en
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000.
   Google Scholar
• Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A veterans administration cooperative study. Jama. 1986;256(11):1449–1455.
   PubMed Web of Science ®Google Scholar
• Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res. 2011;35(10):1749–1758.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Rhines KC, Volpicelli LA, et al. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737–742.
   PubMed Web of Science ®Google Scholar
• Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med. 2007;1(3):115–125.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V, Jandeleit B, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology. 2014;39(4):783–791.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Mann K, Hoffmann S, Pawlak CR. Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics. Neuropsychopharmacology. 2016;41(3):659–660.
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. Addiction. 2012;108:275–293.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Mark TL, Kassed CA, Vandivort-Warren R, et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–349.
   PubMed Web of Science ®Google Scholar
• Collins FS. Mining for therapeutic gold. Nature Rev Drug Discov. 2011;10:397.
   PubMed Web of Science ®Google Scholar
• Placidi F, Diomedi M, Scalise A, et al. Effect of anticonvulsants on nocturnal sleep in epilepsy. Neurology. 2000;54(5 Suppl 1):S25–32.
   PubMed Web of Science ®Google Scholar
• Ehrenberg B. Importance of sleep restoration in co-morbid disease: effect of anticonvulsants. Neurology. 2000;54(5 Suppl 1):S33–7.
   PubMed Web of Science ®Google Scholar
• Mehta N, Bucior I, Bujanover S, et al. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes. 2016;14:54.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47(3):269–277.
   PubMed Web of Science ®Google Scholar
• Canafax DM, Bhanegaonkar A, Bharmal M, et al. Validation of the post sleep questionnaire for assessing subjects with restless legs sydrome: results from two double-blind, multicenter, placebo-controlled clinical trials. BMC Neurology. 2011;11:48.
   PubMed Web of Science ®Google Scholar
• Bazil CW, Battista J, Basner RC. Gabapentin improves sleep in the presence of alcohol. J Clin Sleep Med. 2005;1(3):284–287.
   PubMed Web of Science ®Google Scholar
• Mowla A, Ahmadzadeh L, Jahromi LR, et al. Comparing gabapentin with clonazepam for residual sleeping problems following antidepressant therapy in patients with major depressive disorder: a randomized clinical trial. Clin Drug Investig. 2015;35:513–517.
   PubMed Web of Science ®Google Scholar
• Furey SA, Hull SG, Leibowitz MT, et al. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014;10(10):1101–1109.
   PubMed Web of Science ®Google Scholar
• Rosenberg RP, Hull SG, Lankford DA, et al. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014;10(10):1093–1100.
   PubMed Web of Science ®Google Scholar
• Lo H-S, Yang C-M, Lo HG, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharm. 2010;33:84–90.
   PubMed Web of Science ®Google Scholar
• Yurchesen ME, Guttuso T, McDermott M, et al. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Women’s Health. 2009;18(9):1355–1360.
   PubMed Web of Science ®Google Scholar
• Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psych. 2001;13(3):141–146.
   PubMedGoogle Scholar
• Lavigne JE, Mustian K, Mathew JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300mg versus 900mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479–486.
   PubMed Web of Science ®Google Scholar
• Yasmin S, Carpenter LL, Leon Z, et al. Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. J Affect Disord. 2001;63(1):243–247.
   PubMed Web of Science ®Google Scholar
• Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia. 1999;40(8):1129–1134.
   PubMed Web of Science ®Google Scholar
• Mancino MJ, McGaugh J, Chopra MP, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014;34(2):234–239.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacol. 2012;37:1689–1698.
   PubMed Web of Science ®Google Scholar
• Salehi M, Kheirabadi GR, Maracy MR, et al. Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol. 2011;31(5):593–596.
   PubMed Web of Science ®Google Scholar
• Kheirabadi GR, Ranjkesh M, Maracy MR, et al. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction. 2008;103:1495–1499.
   PubMed Web of Science ®Google Scholar
• Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?. J Clin Psychopharmacol. 2002;22(6):584–591.
   PubMed Web of Science ®Google Scholar
• Wang PW, Santosa C, Schumacher M, et al. Gabapentin augmentation therapy in bipolar depression. Bipolar Disorders. 2002;4:296–301.
   PubMed Web of Science ®Google Scholar
• Biyik Z, Solak Y, Atalay H, et al. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. Int Urol Nephrol. 2013;45:831–837.
   PubMed Web of Science ®Google Scholar
• Roberto M, Gilpin NW, O’Dell LE, et al. Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci. 2008;28(22):5762–5771.
   PubMed Web of Science ®Google Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–113.
   PubMed Web of Science ®Google Scholar
• Xiao W, Boroujerdi A, Bennet GJ, et al. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-s-delta-1 calcium channel subunit. Neuroscience. 2007;144(2):714–720.
   PubMed Web of Science ®Google Scholar
• Uchitel OD, Di Giulmi MN, Urbano FJ, et al. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels (Austin). 2010;4(6):490–496.
   PubMed Web of Science ®Google Scholar
• Fink K, Meder W, Dooley DJ, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol. 2000;130(4):900–906.
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004;20(6):1566–1576.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29(3):233–249.
   PubMed Web of Science ®Google Scholar
• Götz E, Feuerstein TJ, Lais A, et al. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung. 1993;43(6):636–638.
   PubMed Web of Science ®Google Scholar
• Bertrand S, Ng GY, Purisai MG, et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J Pharmacol Exp Ther. 2001;298(1):15–24.
   PubMed Web of Science ®Google Scholar
• Jensen AA, Mosbacher J, Elg S, et al. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol. 2002;61(6):1377–1384.
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276–281.
   PubMed Web of Science ®Google Scholar
• Neurontin (gabapentin capsule; gabapentin tablet, film coated; gabapentin solution) human prescription drug label information. Parke-Davis Division of Pfizer Inc., 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388&type=pdf&name=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 Last accessed 2017 Dec 6
   Google Scholar
• Roberto M, Cruz MT, Gilpin NW, et al. Corticotropin releasing factor-induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol Psychiatry. 2010;67(9):831–839.
   PubMed Web of Science ®Google Scholar
• Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139(2):380–392.
   PubMed Web of Science ®Google Scholar
• Katsura M, Shibasaki M, Hayashida S, et al. Increase in expression of alpha1 and alpha2/delta1 subunits of L-type high voltage-gated calcium channels after sustained ethanol exposure in cerebral cortical neurons. J Pharmacol Sci. 2006;102(2):221–230.
   PubMed Web of Science ®Google Scholar
• Farris SP, Arasappan D, Hunicke-Smith S, et al. Transcriptome organization for chronic alcohol abuse in human brain. Mol Psychiatry. 2015;20(11):1438–1447.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend. 2006;83(1):25–32.
   PubMed Web of Science ®Google Scholar
• Myrick H, Anton R, Voronin K, et al. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcoholism Clin Exp Res. 2007;31(2):221–227.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Light JM, Williams LD, et al. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Bio. 2009;14(1):73–83.
   PubMed Web of Science ®Google Scholar
• Karem-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157(1):151.
   Web of Science ®Google Scholar
• Karem-Hage M, Brower KJ. An open pilot study of gabapentin vs. trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57(5):542–544.
   PubMed Web of Science ®Google Scholar
• Brower KJ, Myra Kim H, Strobbe S, et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429–1438.
   PubMed Web of Science ®Google Scholar
• Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691–1700.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence. A randomized clinical trial. JAMA Intern Med. 2014;174(1):70–77.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/−)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311(1):324–333.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009;29(4):334–342.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709–717.
   PubMed Web of Science ®Google Scholar
• Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addiction. 1989;84:1353–1357.
   PubMedGoogle Scholar
• Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focu on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1106–1117.
   PubMed Web of Science ®Google Scholar
• Hammond CJ, Niciu MJ, Drew S, et al. Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. CNS Drugs. 2015;29:293–311.
   PubMed Web of Science ®Google Scholar
• Leung JG, Hall-Flavin D, Nelson S, et al. Role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015;49(8):897–906.
   PubMed Web of Science ®Google Scholar
• Myrick H, Malcolm R, Randall PK, et al. A double blind trial of gabapentin vs. lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33(9):1582–1588.
   PubMed Web of Science ®Google Scholar
• Trevisan LA, Ralevski E, Keegan K, et al. Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients. Addiction Disorders and Their Treatment. 2008;7(3):119–128.
   Google Scholar
• How gabapentin differs from pregabalin. Pharmacy Times. Cranbury, NJ: Pharmacy & Healthcare Communications, LLC, 2015. Available at: http://www.pharmacytimes.com/contributor/jeffrey-fudin/2015/09/how-gabapentin-differs-from-pregabalin Last accessed 2017 Dec 6
   Google Scholar
• Di Nicola M, Martinotti G, Tedeschi D, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol Clin Exp. 2010;25:268–275.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Frustaci A, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010;105:288–299.
   PubMed Web of Science ®Google Scholar
• Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41(4):399–406.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther. 2008;25(6):608–618.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharm. 2010;24(9):1367–1374.
   PubMed Web of Science ®Google Scholar
• Häkkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.
   PubMed Web of Science ®Google Scholar
• Schjerning O, Pottegård A, Damkier P, et al. Use of pregabalin – a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry. 2016;49(4):155–161.
   PubMed Web of Science ®Google Scholar
• Myrick H, Henderson S, Brady KT, et al. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry. 2001;62:19–23.
   PubMed Web of Science ®Google Scholar
• Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry. 2004;65(1):84–86.
   PubMed Web of Science ®Google Scholar
• Hart CL, Haney M, Voxburg SK, et al. Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav Pharmacol. 2007;18(1):71–75.
   PubMed Web of Science ®Google Scholar
• González G, Desai R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007;87(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Aharonovich E, Garawi F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006;81(3):267–274.
   PubMed Web of Science ®Google Scholar
• Urschel HC 3rd, Hanselka LL, Gromov I, et al. Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc. 2007;82(10):1170–1178.
   PubMed Web of Science ®Google Scholar
• Urschel HC 3rd, Hanselka LL, Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol. 2011;25(2):254–262.
   PubMed Web of Science ®Google Scholar
• Ling W, Shoptaw S, Hillhouse M, et al. Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction. 2012;107(2):361–369.
   PubMed Web of Science ®Google Scholar
• Martínez-Raga J, Sabater A, Perez-Galvez B, et al. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):599–601.
   PubMed Web of Science ®Google Scholar
• Kumar P, Jain MK. Gabapentin in the management of pentazocine dependence: a potent analgesic-anticraving agent. J Assoc Physicians India. 2003;51:673–676.
   PubMedGoogle Scholar
• Ziaaddini H, Ziaaddini A, Asghari N, et al. Trial of tramadol plus gabapentin for opioid detoxification. Iran Red Crescent Med J. 2015;17(1):e18202.
   PubMed Web of Science ®Google Scholar
• Rodríguez De Fonseca F, Carrera MR, Navarro M, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 1997;276(5321):2050–2054.
   PubMed Web of Science ®Google Scholar
• Salinsky MC, Storzbach D, Spencer DC, et al. Effects of topirimate and gabapentin on cognitive abilities in healthy volunteers. Neurology. 2005;64(5). pp-pp, supplement tables E1 and E2.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Backonja M, Schug S, et al. Pregabalin for the treatment of drug and alcohol withdrawal syndrome: a comprehensive review. CNS Drugs. 2016;30(12):1191–1200.
   PubMed Web of Science ®Google Scholar
• Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87(4):763–767.
   PubMed Web of Science ®Google Scholar
• Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘suspected adverse drug reactions’ database. CNS Drugs. 2016;30(7):647–654.
   PubMed Web of Science ®Google Scholar
• Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24(2):173–177.
   PubMed Web of Science ®Google Scholar
• Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–1174.
   PubMed Web of Science ®Google Scholar